General Catalyst Group Management, LLC — 13F Holdings & Portfolio

CIK 1637946 · latest 13F-HR filed 2026-08-17

General Catalyst Group Management, LLC manages $188.5M in 13F-reported U.S. long-equity assets across 14 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are AVBP (27.55%), PBLS (23.24%), CART (17.85%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 4 new positions, exited 2, added to 8, and trimmed 1.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Filer Information
Address
C/O GENERAL CATALYST PARTNERS
20 UNIVERSITY ROAD, 4TH FLOOR
CAMBRIDGE, MA 02138
Phone
(617) 234-7000
Filing Manager
General Catalyst Group Management, LLC
CAMBRIDGE, MA
Signatory
Christopher McCain
Chief Legal Officer
Loading holdings…
AUM

$188.5M

Long-equity book

Holdings

14

Distinct positions

Period

2026-06-30

Filed 2026-08-17

Q/Q Activity

+4 / −2 / ↑8 / ↓1

vs 2026-03-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • ArriVent BioPharma, Inc.$17.4M +50.6%
  • Maplebear, Inc.$7.0M +26.4%
  • Fractyl Health, Inc.$1.6M +73.5%
  • Eikon Therapeutics, Inc.$753.9K +23.3%
  • Ethos Technologies, Inc.$517.0K +62.4%
Show all 8

Top Trims

  • Figma, Inc.-$45.3K -14.4%
Show all 1

New Positions

  • Parabilis Medicines, Inc.$43.8M
  • Odyssey Therapeutics, Inc.$15.2M
  • Doordash Inc.$525.9K
  • Carvana Co$425.5K
Show all 4

Exited Positions

  • SAMSARA INC$63.4M
  • GITLAB INC$19.9M
Show all 2
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 ArriVent BioPharma, Inc. AVBP 04272N102 $51.9M 27.55% 1,494,786 SH
2 Parabilis Medicines, Inc. PBLS 698955101 $43.8M 23.24% 1,600,937 SH
3 Maplebear, Inc. CART 565394103 $33.7M 17.85% 710,711 SH
4 Maze Therapeutics, Inc. MAZE 578784100 $30.9M 16.40% 1,035,910 SH
5 Odyssey Therapeutics, Inc. ODTX 67613T104 $15.2M 8.04% 810,272 SH
6 Eikon Therapeutics, Inc. EIKN 282564103 $4.0M 2.11% 305,233 SH
7 Fractyl Health, Inc. GUTS 35168W103 $3.9M 2.06% 4,884,186 SH
8 Ethos Technologies, Inc. LIFE 29765A101 $1.3M 0.71% 74,179 SH
9 Coupang Inc. CPNG 22266T109 $949.7K 0.50% 54,677 SH
10 Amazon.com Inc. AMZN 023135106 $925.2K 0.49% 3,882 SH
11 Meta Platforms Inc. META 30303M102 $743.5K 0.39% 1,320 SH
12 Doordash Inc. DASH 25809K105 $525.9K 0.28% 2,850 SH
13 Carvana Co CVNA 146869102 $425.5K 0.23% 6,465 SH
14 Figma, Inc. FIG 316841105 $268.5K 0.14% 14,845 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-17 $188.5M 14 0001637946-26-000002
2026-03-31 2026-05-15 $183.6M 12 0000905148-26-002373
2025-12-31 2026-02-17 $221.7M 7 0000905148-26-000847
2025-09-30 2025-11-14 $3.04B 8 0000905148-25-004012